Literature DB >> 8914679

Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis.

S Nishimura1, K Nishiya, N Hisakawa, H Chikazawa, S Ookubo, K Nakatani, K Hashimoto.   

Abstract

Some patients with rheumatoid arthritis (RA) as well as those with other collagen diseases are positive for antinuclear antibody (ANA). We investigated the frequency of positivity for ANA in 104 patients with RA and evaluated the clinical features and laboratory data in the ANA-positive and -negative groups. The presence of ANA in sera was studied by indirect immunofluorescence using HEp-2 cells as the antigen substrate. Sera with a positive fluorescence at a dilution of 1:20 were considered to be positive for ANA. Of the 104 patients, 39 (37.5%) were positive for ANA. The staining pattern in the positive cases varied, but most were speckled (64.1%) and homogeneous (48.7%). A small number showed a nucleolar (20.5%) or a centromere (10.3%) pattern. None showed a shaggy pattern. The ANA titer was lower in RA patients compared with those with other collagen-related diseases such as systemic lupus erythematosus or progressive systematic sclerosis. None of the patients positive for ANA with either a nucleolar or centromere staining pattern had progressive systemic sclerosis or the CREST syndrome. One patient each had Raynaud's phenomenon and pulmonary fibrosis. There was no correlation between ANA positivity and indicators of joint inflammation. The prevalence of ANA positivity in patients with advanced or prolonged disease was higher than those with early stages or short durations. There was no correlation with drug therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914679     DOI: 10.18926/AMO/30501

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  7 in total

1.  Rheumatic disease among Oklahoma tribal populations: a cross-sectional study.

Authors:  Jasmine R Gaddy; Evan S Vista; Julie M Robertson; Amy B Dedeke; Virginia C Roberts; Wendy S Klein; Jeremy H Levin; Fabio H Mota; Tina M Cooper; Gloria A Grim; Sohail Khan; Judith A James
Journal:  J Rheumatol       Date:  2012-08-15       Impact factor: 4.666

2.  [Clinical and laboratory characteristics of rheumatoid arthritis with positive antinuclear antibody].

Authors:  J F Zhang; X L Ye; M Duan; X L Zhou; Z Q Yao; J X Zhao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

3.  The association of Raynaud's syndrome with rheumatoid arthritis--a meta-analysis.

Authors:  Peter Hartmann; Melvin Mohokum; Peter Schlattmann
Journal:  Clin Rheumatol       Date:  2011-04-02       Impact factor: 2.980

Review 4.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

5.  Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis.

Authors:  Yoo Seob Shin; Jeong Hee Choi; Dong Ho Nahm; Hae Sim Park; Jae Hyun Cho; Chang Hee Suh
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

6.  Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.

Authors:  Gunter Assmann; Klara Shihadeh; Viola Poeschel; Niels Murawski; Jutta Conigliarou; Mei Fang Ong; Michael Pfreundschuh
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

7.  Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice.

Authors:  Maria M Dimitriadou; Haris Alexopoulos; Sofia Akrivou; Eleni Gola; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.